New combo therapy aims to wipe out stubborn myeloma cells
NCT ID NCT05497804
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests a combination of four drugs (carfilzomib, daratumumab, lenalidomide, and dexamethasone) in 17 people with high-risk multiple myeloma. The goal is to see if the treatment can clear even tiny amounts of cancer left after initial therapy, known as minimal residual disease. Participants receive the drugs and undergo regular blood tests and bone marrow biopsies to track their response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
carfilzomib, daratumumab, lenalidomide, and dexamethasone
What this could lead to
If successful, this could lead to a more effective treatment strategy for high-risk multiple myeloma, potentially helping patients achieve longer remission.
What could go wrong
This is a small, early-phase trial with only 17 participants, so results may not apply to all patients. The drug combination also has known side effects like fatigue and infection risk.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic
Jacksonville, Florida, 32224-9980, United States
-
Mayo Clinic in Arizona
Scottsdale, Arizona, 85259, United States
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States